Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) EPS (Weighted Average and Diluted) (2021 - 2025)

Mirum Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 5 years, most recently at -$0.12 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.12 for Q4 2025, up 75.51% from a year ago — trailing twelve months through Dec 2025 was -$0.49 (up 73.51% YoY), and the annual figure for FY2025 was -$0.47, up 74.59%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.12 at Mirum Pharmaceuticals, down from $0.05 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for MIRM hit a ceiling of $1.91 in Q4 2021 and a floor of -$1.94 in Q2 2023.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.57 (2023), compared with a mean of -$0.6.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 151.83% in 2022 and later soared 116.67% in 2025.
  • Mirum Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $1.91 in 2021, then crashed by 151.83% to -$0.99 in 2022, then increased by 27.27% to -$0.72 in 2023, then surged by 31.94% to -$0.49 in 2024, then soared by 75.51% to -$0.12 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.12 (Q4 2025), $0.05 (Q3 2025), and -$0.12 (Q2 2025) per Business Quant data.